Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;182(12):1326-1328.
doi: 10.1001/jamainternmed.2022.4954.

Rate of Recurrence After Discontinuing Anticoagulation Therapy in Patients With COVID-19-Associated Venous Thromboembolism

Luis Jara-Palomares  1   2 , Behnood Bikdeli  3   4   5   6 , David Jiménez  7   8   9 , Alfonso Muriel  10   11 , Mar Martin Del Pozo  12 , Pablo Demelo-Rodríguez  13 , Manuel Monreal  14
Affiliations

Rate of Recurrence After Discontinuing Anticoagulation Therapy in Patients With COVID-19-Associated Venous Thromboembolism

Luis Jara-Palomares et al. JAMA Intern Med. .
No abstract available

Plain language summary

This cohort study assesses the rate of recurrence of venous thromboembolism (VTE) in patients with COVID-19–associated VTE who discontinued anticoagulation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Jara-Palomares reported receiving grants from Leo Pharma and MSD and receiving personal fees from Daichii, Rovi, GlaxoSmithKline, and Actellion outside the submitted work. Dr Bikdeli reported being a consulting expert on behalf of the plaintiff for litigation related to 2 brand models of inferior vena cava filters. Dr Jimenez reported receiving personal fees from Pfizer, Bristol Myers Squibb, Daiichi Sankyo, Rovi, and Leo Pharma outside the submitted work. Dr Demelo-Rodríguez reported receiving personal fees from Sanofi, Leo Pharma, Bayer, ROVI, Menarini, and Pfizer outside the submitted work. Dr Monreal reported grants from Sanofi and Rovi outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Incidence Curve for Recurrent Venous Thromboembolism
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Moores LK, Tritschler T, Brosnahan S, et al. . Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020;158(3):1143-1163. doi:10.1016/j.chest.2020.05.559 - DOI - PMC - PubMed
    1. Spyropoulos AC, Levy JH, Ageno W, et al. ; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis . Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865. doi:10.1111/jth.14929 - DOI - PMC - PubMed
    1. Stevens SM, Woller SC, Baumann Kreuziger L, et al. . Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):2247-2259. doi:10.1016/j.chest.2021.07.056 - DOI - PubMed
    1. Bikdeli B, Jimenez D, Hawkins M, et al. ; RIETE Investigators . Rationale, design and methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thromb Haemost. 2018;118(1):214-224. doi:10.1160/TH17-07-0511 - DOI - PMC - PubMed
    1. Iorio A, Kearon C, Filippucci E, et al. . Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-1716. doi:10.1001/archinternmed.2010.367 - DOI - PubMed

Publication types

MeSH terms